SALIM BOUNOU

BOUNOU Salim

Ecole EUROMED d’ingénieurs BiomedTech

s.bounou@ueuromed.org

+212(0)538 990 3213

Postdoctorat, Vrije University of Amsterdam, Nederlands (2003-2003) PostDoctorat

Université Laval (Québec-Canada) 1994-1996 Philosophiae Doctor (Ph.D.)

Université Laval (Québec-Canada) 1998-2002 Master of Science (Ph.D.)

Université Mohamed V (Rabat-Maroc) 1987-1991 Bachelor (B.SC)

 

Formation additionnelle 

 

Technology development and commercialization

Réseau inter-universitaire pour la Valorisation des produits de la Recherche, Interval, Montréal, Canada (2005-2006)

Expertise in management of innovation

Alliance for Commercialization of Canadian Technologies (ACCT) (2006, 2007, 2008)

Patentability opinions, validity and counterfeiting opinions, patent applications, international patent purchases, negotiation of licensing agreements, and mergers / acquisitions.

Intellectual Property Expertise Offices training (2006, 2007, 2008, 2009):

Robic, Norton Rose, BCF, Smart & Biggar, Fasken Martineau

 

Distinctions et prix

 

Fellowship                 Canadian Institutes of Health Research (CIHR)                               2003 - 2006             

Post-Doctoral-Fellow           Rockefeller University, New York, USA                                            2002-2003

Ph.D. scholarship                 Canadian Institutes of Health Research (CIHR)                               2001-2004  

Ph.D. scholarship                 FCAR-FRSQ, Québec, Canada                                                     1999-2001 

Full Scholarships (8 fold)    International conferences in medical sciences                   between 2001-2003    

Virologie

Système immunitaire

Migration cellulaire - cell-based drug delivery system

Biologie moléculaire et biotechnologie

Enseignement des sciences

Propriété intellectuelle et mangement de l’innovation

2019 to today Professor and Dean of Pole of Health 

Université Euro-Méditerranéenne de Fès (UEMF)

http://www.ueuromed.org/pro/fr/

2013 to 2018 Professor, Chargé de mission auprès du Président,

Université Euro-Méditerranéenne de Fès (UEMF)

http://www.ueuromed.org/pro/fr/

2011-2013 Projects Director –Technology Transfer Manager

Gestion Socpra Sec. & Université de Sherbrooke TransferTech

Sherbrooke, CANADA https://www.transfertech.ca/

2009-2011 Director of MAScIR Valor

Fondation MAScIR

Moroccan Foundation for Advanced Sciences, Innovation and Research, Rabat, Morocco http://www.mascir.com/

2007-2009 Projects Director –Technology Transfer Manager

Gestion Socpra Sec. & Université de Sherbrooke

Sherbrooke, CANADA https://www.transfertech.ca/

2003-2009 Professor-Researcher

Université de Sherbrooke

Sherbrooke, CANADA www.usherbrooke.ca

1995, 1996, 1997 Assistant d’enseignement

Université Laval

Québec, CANADA www.ulaval.ca

  Benmoussa Othmane, Slighoua Mounia, Bachiri Housseine, Bounou Salim. Entrepreneurship and Traditional Know-How: The Case of Moroccan Rural Women. EMNES WORKING PAPER n° … / December 6, 2019 under edition 

Côté SC, Pasvanis S, Bounou S, Dumais N. CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: Involvement of EP(2)/EP(4) receptors activation. Mol Immunol. 2009 Aug;46(13):2682-93. Epub 2009 Jul 9.

Boisvert M, Côté S, Vargas A, Pasvanis S, Bounou S, Barbeau B, Dumais N. PGJ2 antagonizes NF-kappaB-induced HIV-1 LTR activation in colonic epithelial cells. Virology. 2008 Oct 10;380(1):1-11. Epub 2008 Aug 27.

Michel Ouellet,* Simon Mercier,* Isabelle Pelletier,† Salim Bounou,* Jocelyn Roy,* Jun Hirabayashi,‡ Sachiko Sato,2† and Michel J. Tremblay2*2005. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J.Immunol. 2005 Apr 1;174(7):4120-6.

Bounou, S., Giguère, J.-F., Cantin, R., Gilbert, C., Imbeault, M., Martin G., Tremblay, M.J, 2004. The importance of virus-bound host ICAM-1 in HIV-1 transfer depends on the cellular context. FASEB J. 2004 Aug 1, 2004; 18 (11)

Salim Bounou*, Jean-François Giguère*, Jean-Sébastien Paquette and Michel J. Tremblay 2004. Incorporation of host CD80 (B7.1) and CD86 (B7.2) glycoproteins into HIV-1 increases viral infectivity in primary human mononuclear cells. J Virol. 2004 Jun;78(12):6222-32.

Dumais N, Pare ME, Mercier S, Bounou S, Marriot SJ, Barbeau B, Tremblay MJ., 2003. T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment lead to potent activation of human T-cell leukemia virus type transcription. J Virol. 2003 Oct 15;77(20):11170-11179.

Jean-François Giguère, Jean-Sébastien Paquette, Salim Bounou, and Michel J. Tremblay, 2002. New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus human immunodeficiency virus type 1. J. Immunol. 2002 Sep 1;169(5):2762-71.

Bounou, Jacques E. Leclerc, and Michel. J. Tremblay, 2002. The presence of host ICAM-1 in laboratory and clinical strains of HIV-1 increases virus infectivity and CD4+ T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J. Virol. 2002 Feb 1;76(3):1004-1014

 Nancy Dumais, Salim Bounou, Martin Olivier and Michel J. Tremblay, 2002. The CCAAT/Enhancer-binding protein is required for mediating cAMP responsiveness on HIV-1 LTR-driven gene activity in T cells mediated by prostaglandin E2. J. Immunol. 2002 Jan 1;168(1):274-82.

Salim Bounou, Dumais Nancy, Tremblay Michel J, 2001. Attachment of HIV-1 particles bearing host-encoded B7-2 proteins leads to NF-B- and NFAT-dependent activation of HIV-1 LTR transcription. J Biol Chem. 2001 Mar 2;276(9):6359-69.

 Salim Bounou, Suha H. Jabaji-Hare, Richard Hogue and Pierre M. Charest, 1999. Polymerase chain reaction-based assay for specific detection of Rhizoctonia solani AG-3 isolates.  Mycological Research Vol 103, part 1, p.1-8.     

Innovation et Valorisation de la recherche-Éléments juridiques.  MedBiotech Conférences. Faculté de médicine et de pharmacie de Rabat, Maroc, 19 décembre 2019. 

Les différents types de contrats recherche publique‐entreprise et transferts, Ententes de licence- Les bases de la négociation. CNRST, Rabat, Maroc. 31 octobre et 1 novembre 2019.

Les éléments juridiques de la valorisation de la recherche. CNRST, Rabat, Maroc. 23 juillet 2016

First analysis of potential innovation and assessment of needs to improve valorization of research results. ARIMNET. 11 juin 2014 - Campus de la Gaillarde INRA-SupAgro, Montpellier, France.

Knowledge enhancement and technology transfer. 30 juin 2012, Compétences Médicales Marocaines du Monde (C3M) &Faculté de médicine de Casablanca, Maroc.

Valorisation et essaimage technologique : Point de vue de l’Université de Sherbrooke. Journée sur la valorisation des résultats de la recherche, Université Mohammed V- Souissi, 7 mai 2009, Rabat, Maroc. 

Maintain competitive advantage through innovation. 23 octobre 2008, IBM-Bromont, Canada.

La gestion de la propriété intellectuelle et commercialisation des produits de la recherche à l’Université de Sherbrooke. Faculté d’Administration, Université de Sherbrooke, 20 mai 2008, Sherbrooke, Canada et Touraine Board of Trade - Chamber of Commerce Touraine.

New therapeutic strategy to counter bacterial and viral infections. A Biopharmaceutical Partnership Symposium, special meeting of industry leaders, October 3, 2007, Château Frontenac, Québec, Canada.

Plasminic biosensor based on semiconductor. Workshop on innovating industrial processes applied to new materials Hotel DELTA, October 2nd , 2007,  Sherbrooke, Canada.

An device for rapid detection of infectious agents. The Canadian Institute for Photonic Innovations, a Network of Centers of Excellence. October 20th, 2006, Montréal, Canada.

Host Proteines incorporated in HIV envelope : Pathogenesis. Health Products and Food Branch, Bureau of Microbial Hazards, Health Canada, Sir Frederick G. Banting Research Centre, Tunney's Pasture, P. L. 2204A2, February 15, 2005, Ottawa, Ontario. Canada.

Microbiologie

Immunologie

Biologie cellulaire

Biologie moléculaire

Biotechnologie médicale

Management de l’innovation, Entreprenariat